Pennant Investors, LP Nurix Therapeutics, Inc. Transaction History
Pennant Investors, LP
- $367 Million
- Q2 2024
A detailed history of Pennant Investors, LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Pennant Investors, LP holds 56,800 shares of NRIX stock, worth $1.37 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
56,800
Previous 56,800
-0.0%
Holding current value
$1.37 Million
Previous $834,000
42.09%
% of portfolio
0.32%
Previous 0.21%
Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
183Shares Held
66.3MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$164 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$106 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$96.1 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$93.4 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$87.3 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.13B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...